(MENAFN- GlobeNewsWire - Nasdaq) Emerging technologies in diagnostics and telemedicine are transforming patient management, although high costs and variable patient responses remain barriers. With growing investments in dermatological research, demand is driven by the aging population and advanced diagnostic techniques. Key market players include Sanofi, Regeneron, and Amgen.

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
Bullous pemphigoid, a rare, chronic autoimmune disorder characterized by large, tense blisters on the skin, significantly impacts the quality of life of affected individuals. It primarily affects older adults and can result in severe complications, including secondary skin infections and scarring. The progression of the disease can lead to significant morbidity if not properly managed.
However, challenges including the high cost of these emerging therapies, the variability in patient responses, and limited access to healthcare resources in low- and middle-income countries remain significant barriers. Additionally, the rarity of bullous pemphigoid, combined with the potential for misdiagnosis or delayed diagnosis, particularly in patients with atypical presentations, complicates the treatment landscape. Despite these challenges, the increasing government and private sector investments in dermatological and autoimmune disease research are expected to drive further growth in the BP market.
Impact
Technological advancements in diagnostic imaging, biomarker testing, and telemedicine are greatly improving the early detection and personalized management of bullous pemphigoid. Innovations such as serological testing, AI-driven models for disease progression, and advanced imaging techniques are enhancing diagnostic accuracy and treatment monitoring. Additionally, the integration of digital health platforms and remote patient management tools is increasing access to care, especially in underserved areas, facilitating continuous monitoring, improving patient adherence to treatment, and enabling more tailored therapeutic approaches for better disease management and outcomes.
Systemic therapies currently hold the highest market share in the bullous pemphigoid market. This is largely due to their widespread use in managing moderate to severe forms of BP, especially in patients with extensive blistering or those not responding to topical treatments. Systemic corticosteroids, such as prednisone, are the cornerstone of BP treatment, often combined with immunosuppressants such as azathioprine or mycophenolate mofetil to reduce inflammation and prevent flare-ups.
North America holds the highest market share in the bullous pemphigoid market, driven by the region's advanced healthcare infrastructure, high rates of early diagnosis, and access to a wide range of treatment options, including systemic therapies and biologic treatments. The U.S. in particular has a well-established dermatology market, with significant investment in autoimmune disease research and development, leading to the availability of innovative therapies.
Demand Drivers for the Global Bullous Pemphigoid Market:

• As bullous pemphigoid primarily affects elderly individuals, the increasing global aging population is a significant driver of demand.
• Improved diagnostic methods, such as serological tests and non-invasive imaging techniques, are enabling earlier detection of BP.
• The expansion of healthcare infrastructure, particularly in developing countries, along with the growing use of telemedicine and remote monitoring platforms, is increasing patient access to timely and accurate care.
• The development of new biologic therapies and the promise of treatments such as rituximab are fuelling demand.

Limitations for the Global Bullous Pemphigoid Market:

• Biologic therapies and specialized treatments for BP are often costly, limiting their accessibility, especially in low- and middle-income countries.
• Although biologic therapies are promising, their availability is still limited due to high costs and complex administration.
• Patients with BP exhibit differing responses to treatments, complicating treatment regimens and extending the time required for optimal management.

Key Market Players and Competition Synopsis
The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global bullous pemphigoid market.
Leading players in the global bullous pemphigoid market include:

• Sanofi
• Regeneron Pharmaceuticals
• Amgen Inc.
• Johnson & Johnson
• Chugai Pharmaceutical
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd

Key Topics Covered:
1. Global Bullous Pemphigoid Market: Industry Analysis
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
2. Global Bullous Pemphigoid Market (by Therapy Type), Value ($million), 2023-2035
2.1 Topical Therapies
2.2 Systemic Therapies
2.3 Biologic Therapies
2.4 Plasmapheresis
2.5 Immunosuppressants
3. Global Bullous Pemphigoid Market (by Region), Value ($Million), 2023-2035
3.1 North America
3.2 Europe
3.3 Asia-Pacific
3.4 Rest-of-the-World
4. Competitive Landscape and Company Profiles
4.1 Competitive Landscape
4.1.1 Mergers and Acquisitions
4.1.2 Partnership, Alliances and Business Expansion
4.1.3 New Offerings
4.1.4 Regulatory Activities
4.1.5 Funding Activities
4.2 Company Profiles

• Sanofi
• Regeneron Pharmaceuticals
• Amgen Inc.
• Johnson & Johnson
• Chugai Pharmaceutical
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06102025004107003653ID1110156497